List view / Grid view
The partnership between Eli Lilly and Company and Creyon Bio will focus on producing safer, more effective RNA-targeted oligonucleotide therapies with the use of AI technology.
The company now has ABPI membership after a two-year suspension involving concerns relating to its compliance with the industry body’s code of conduct.
The biopharmaceutical company’s executive transition follows a multi-year succession process to support its next chapter.
Cutting-edge science and large international investment are driving growth in the UK’s biotech sector, the organisation’s new report reveals.
The US$570m investment will contribute to advancing AstraZeneca’s global clinical pipeline, a key goal of its strategy to 2030.
Eleven drugs are poised to make waves in the pharmaceutical industry in 2025, according to the annual report.
The positive opinion means HIV patients could overcome challenges of taking daily oral regimens, says ViiV Healthcare's Chief Medical Officer.
The new treatment option provides a convenient alternative to currently available vials of the bispecific antibody for EU patients with common vision conditions.
The innovative line of barrier bottles provides unmatched protection against moisture and oxygen and reduces production costs, LOG Pharma Primary Packaging says.
This bioproduction investment in Lyon, France supports Sanofi in its goals to lead in the immunology sector.
Research and innovation is highlighted in the UK’s Autumn Budget as a priority ‘crucial national asset’ to aid long-term economic growth.
The new appointee will create AI and machine learning solutions to support Eli Lilly’s medicines for patients globally.
The new manufacturing facility in Finland will aid global supply of the first FDA-approved intravesical non-replicating gene therapy for adults with a common cancer.
Sanofi’s novel manufacturing unit in France shortens production timelines and enables rapid changes in production capacities for medicines such as biologics and vaccines.
The multi-target biologic-focused agreement could enhance treatment convenience by improving subcutaneous administration options for patients.
